Calreticulin (CRT), an eat-me signal displayed on the plasma membrane, is recognized by antigen-presenting cells (APCs), and then tumor-derived antigens are presented to prime and activate specific T cells [98]. The gene discussed is CALR; the disease is neoplasm.